

The following are the Medications Development Centers currently part of the NIDA Principal Investigator

Cocaine Pharmacotherapy Targeting Dopamine & GABA

Thomas R. Kosten, M.D.

This Center for Medications Development (MDU) has a track record in developing new GABA and dopamine

Center for Research Improving Treatment of Drug Abuse

Charles P. O'Brien, M.D.

This is a P60 Center that was formed in 1987 with the goal of improving treatment of addiction. Projects

Innovative Approaches for Cocaine Pharmacotherapy

Helen M. Pettinati, Ph.D.

This is a NIDA-funded P50 Research Center that focuses on the development of new medications for the

Methamphetamine Pharmacotherapy Development Center

John Mendelson, M.D.

Methamphetamine abuse is a widespread problem. This project will test the safety and efficacy of new

Novel Medications Approaches for Substance Abuse

Herbert D. Kleber, M.D.

The current MDRC has a goal to develop new, effective medications for, subgroups of

Substance Abuse Research

F. Gerard Moeller, M.D.

Medications Development Center

Cocaine abuse alone, and co-occurring with heroin and benzodiazepine abuse, has led to a significant

UCLA Medication Development Unit for Stimulant Abuse
Steven Shoptaw, Ph.D.

The thematic emphasis that unifies this continuation of the existing Medication Development Unit for Stimulant Abuse is the focus on the development of novel, safe, and effective treatments for stimulant use disorders.